Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 25:11:626309.
doi: 10.3389/fonc.2021.626309. eCollection 2021.

Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies

Affiliations
Review

Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies

Malina Xiao et al. Front Oncol. .

Abstract

Autophagy is a highly regulated multi-step process that occurs at the basal level in almost all cells. Although the deregulation of the autophagy process has been described in several pathologies, the role of autophagy in cancer as a cytoprotective mechanism is currently well established and supported by experimental and clinical evidence. Our understanding of the molecular mechanism of the autophagy process has largely contributed to defining how we can harness this process to improve the benefit of cancer therapies. While the role of autophagy in tumor resistance to chemotherapy is extensively documented, emerging data point toward autophagy as a mechanism of cancer resistance to radiotherapy, targeted therapy, and immunotherapy. Therefore, manipulating autophagy has emerged as a promising strategy to overcome tumor resistance to various anti-cancer therapies, and autophagy modulators are currently evaluated in combination therapies in several clinical trials. In this review, we will summarize our current knowledge of the impact of genetically and pharmacologically modulating autophagy genes and proteins, involved in the different steps of the autophagy process, on the therapeutic benefit of various cancer therapies. We will also briefly discuss the challenges and limitations to developing potent and selective autophagy inhibitors that could be used in ongoing clinical trials.

Keywords: autophagy; cancer resistance; chemotherapy; immunotherapy; radiotherapy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
General presentation of the major steps of autophagy. Several stimuli have been identified to induce autophagy such as hypoxia, starvation, and cancer therapies. The major steps of autophagy are: 1) Initiation, 2) Nucleation, 3) Maturation, and 4) Fusion with lysosome for the degradation and recycling of autophagosome constituents.
Figure 2
Figure 2
Schematic representation of proteins involved in the major steps of autophagy. Genetic or pharmacological approaches targeting proteins involved in each step of autophagy are reported in squares.

References

    1. De Duve C, Wattiaux R. Functions of lysosomes. Annu Rev Physiol (1966) 28:435–92. 10.1146/annurev.ph.28.030166.002251 - DOI - PubMed
    1. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer (2017) 17(9):528–42. 10.1038/nrc.2017.53 - DOI - PMC - PubMed
    1. Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, et al. . Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res (2011) 71(18):5976–86. 10.1158/0008-5472.CAN-11-1094 - DOI - PubMed
    1. Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, et al. . Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 4:e838. 10.1038/cddis.2013.350 - DOI - PMC - PubMed
    1. Palorini F, Cozzarini C, Gianolini S, Botti A, Carillo V, Iotti C, et al. . First application of a pixel-wise analysis on bladder dose-surface maps in prostate cancer radiotherapy. Radiother Oncol (2016) 119(1):123–8. 10.1016/j.radonc.2016.02.025 - DOI - PubMed

LinkOut - more resources